According to a recent LinkedIn post from Truveta, recent findings from Truveta Research featured in USA TODAY indicate that prescriptions for estrogen-based hormone replacement therapy, HRT, more than doubled between 2018 and 2026. The post notes that one of the largest increases was in patch-based therapies, which may be contributing to current supply constraints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that rising demand, evolving clinical guidance, and patient awareness are creating both access challenges and a need for better visibility into real-world treatment trends. For investors, Truveta’s role in supplying real-world data to inform care, policy, and access decisions may signal growing commercial opportunities in data analytics and evidence generation for life sciences firms, payers, and providers.
Featuring Truveta Research in a major outlet such as USA TODAY could enhance the company’s brand recognition and credibility among healthcare stakeholders. This visibility may strengthen Truveta’s competitive position in the real-world data and health analytics market, potentially supporting future customer acquisition and partnership activity.